Who is sponsoring NCT04723446?

NCT04723446 is sponsored by Queen Mary University of London.

What drugs are being tested in NCT04723446?

Interventions in NCT04723446: Corsodyl® Alcohol free -0.2 % Chlorhexidine digluconate, Colgate Peroxyl® -1.5% Hydrogen peroxide, Oral-B® Gum & Enamel Care -Cetylpyridinium chloride, No rinsing.

What condition does NCT04723446 study?

NCT04723446 studies Covid19, Coronavirus.

Is NCT04723446 still recruiting?

NCT04723446 is currently completed. Last updated 14 September 2023.

Last reviewed 2023-09-14 · How we verify

NCT04723446: COVID-19

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Efficacy of Mouthwashes in Reducing Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Viral Load in the Saliva

Completed NA Last updated 14 September 2023

What this trial tests

NA trial testing Corsodyl® Alcohol free -0.2 % Chlorhexidine digluconate in Covid19 in 54 participants. Completed in 25 October 2021.

Timeline

19 May 2021

Primary endpoint
25 October 2021

25 October 2021

Quick facts

Lead sponsor	Queen Mary University of London
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	other
Enrollment	54
Start date	19 May 2021
Primary completion	25 October 2021
Estimated completion	25 October 2021
Sites	2 locations across United Kingdom

Drugs / interventions tested

Corsodyl® Alcohol free -0.2 % Chlorhexidine digluconate — full drug profile →
Colgate Peroxyl® -1.5% Hydrogen peroxide — full drug profile →
Oral-B® Gum & Enamel Care -Cetylpyridinium chloride
No rinsing

Conditions studied

Covid19 — all drugs for Covid19 →
Coronavirus — all drugs for Coronavirus →

Sponsor

Queen Mary University of London

Who can join

18 and older, any sex, with Covid19 or Coronavirus. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a single-blind, parallel-group, randomized pilot study designed to evaluate and compare the efficacy of 3 different mouthwashes containing 0.2% Chlorhexidine digluconate, 1.5% Hydroxide peroxide or Cetylpyridinium chloride in reducing Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral load in the saliva of COVID-19 positive patients at different time-points. A convenient sample of up to 40 COVID-19 positive patients diagnosed via test and/or presenting COVID-19 clinical symptoms will be identified in the inpatients and/or outpatient clinics at the Newham University Hospital and at The Royal London Hospital, Barts Health National Health Service (NHS) Trust, United Kingdom (UK). The study will consist of one visit. Unstimulated saliva samples will be collected from all COVID-19 positive patients before and at 30 minutes, 1, 2, and 3 hours after mouth rinsing (Group 1-3 ) or no rinsing (Group 4). Viral load analysis of saliva samples in the different time-points will be then assessed by Reverse Transcription quantitative PCR (RT- qPCR).

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Efficacy of three antimicrobial mouthwashes in reducing SARS-CoV-2 viral load in the saliva of hospitalized patients: a randomized controlled pilot study.
Perussolo J, Teh MT, Gkranias N, Tiberi S, et al · · 2023 · cited 6× · PMID 37542087 · DOI 10.1038/s41598-023-39308-x

Verify or expand the search:

Other recruiting trials for Covid19

Currently open trials in the same condition.

NCT03305341 — Proof-of-Concept Clinical Pharmacology Trial for COVID-19 Antigen Presentation Therapeutic Biologic Mix · EARLY_PHASE1 · active not recruiting
NCT06482138 — Dysfunction of Olfaction After COVID-19 Infection: Morphological and Histomolecular Investigation · NA · recruiting
NCT04924803 — Community Developed Technology-Based Messaging to Increase COVID-19 Vaccine Uptake Among People Who Inject Drugs · NA · active not recruiting
NCT05013632 — COVID-19 International Drug Pregnancy Registry · recruiting
NCT04806061 — Urine Alkalinisation in COVID-19 · NA · active not recruiting

Other Queen Mary University of London trials

Trials by the same sponsor.

NCT07246005 — LVT DURATION: Pilot Study of Anticoagulation Duration for Left Ventricular Thrombus · Phase 2 · not yet recruiting
NCT07165678 — CTCA Prior to Invasive Angiography in Post-Bypass Patients (BYPASS CTCA 2) · NA · not yet recruiting
NCT06937372 — Delivery and Implementation of a Randomised Crossover Trial on Thrombosis · NA · not yet recruiting
NCT06600438 — Slow-SPEED UK: A Double-Blind Randomised Feasibility Trial · NA · not yet recruiting
NCT06987045 — Trans and Non-binary Prostate-Specific Antigen Reference Interval Determination Study · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04723446 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Queen Mary University of London
Last refreshed: 14 September 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04723446.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing